These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20954880)

  • 1. Commercially available assays for multiplex detection of alpha human papillomaviruses.
    Poljak M; Kocjan BJ
    Expert Rev Anti Infect Ther; 2010 Oct; 8(10):1139-62. PubMed ID: 20954880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.
    Hesselink AT; Sahli R; Berkhof J; Snijders PJ; van der Salm ML; Agard D; Bleeker MC; Heideman DA
    J Clin Virol; 2016 Mar; 76():36-9. PubMed ID: 26809131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Validation of Anyplex II HPV HR Detection Test for Cervical Cancer Screening in Korea.
    Jung S; Lee B; Lee KN; Kim Y; Oh EJ
    Arch Pathol Lab Med; 2016 Mar; 140(3):276-80. PubMed ID: 26927723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
    Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
    Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a new HPV genotyping assay based on next-generation sequencing.
    Yi X; Zou J; Xu J; Liu T; Liu T; Hua S; Xi F; Nie X; Ye L; Luo Y; Xu L; Du H; Wu R; Yang L; Liu R; Yang B; Wang J; Belinson JL
    Am J Clin Pathol; 2014 Jun; 141(6):796-804. PubMed ID: 24838323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.
    Zhao FH; Lewkowitz AK; Chen F; Lin MJ; Hu SY; Zhang X; Pan QJ; Ma JF; Niyazi M; Li CQ; Li SM; Smith JS; Belinson JL; Qiao YL; Castle PE
    J Natl Cancer Inst; 2012 Feb; 104(3):178-88. PubMed ID: 22271765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HPV detection methods and genotyping techniques in screening for cervical cancer.
    Eide ML; Debaque H
    Ann Pathol; 2012 Dec; 32(6):e15-23, 401-9. PubMed ID: 23244480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance and Diagnostic Accuracy of Human Papillomavirus Testing on Self-Collected Urine and Vaginal Samples in a Referral Population.
    Cho HW; Hong JH; Min KJ; Ouh YT; Seong SJ; Moon JH; Cho SH; Lee JK
    Cancer Res Treat; 2021 Jul; 53(3):829-836. PubMed ID: 33421987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
    Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
    J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the clinical performances of the AdvanSure HPV Screening Real-Time PCR, the Abbott Real-Time High-Risk HPV Test, and the Hybrid Capture High-Risk HPV DNA Test for Cervical Cancer Screening.
    Chung HS; Hahm C; Lee M
    J Virol Methods; 2014 Sep; 205():57-60. PubMed ID: 24814874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput genotyping of high-risk HPV by the digene HPV Genotyping LQ Test using GP5+/6+-PCR and xMAP technology.
    Geraets DT; Heideman DA; de Koning MN; Snijders PJ; van Alewijk DC; Meijer CJ; van Doorn LJ; Quint WG
    J Clin Virol; 2009 Nov; 46 Suppl 3():S21-6. PubMed ID: 20129070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High genotyping concordance between the digene HPV Genotyping RH Test and the Reverse Line Blot genotyping assay on GP5+/6+-PCR products.
    Geraets DT; Heideman DA; de Koning MN; Snijders PJ; Meijer CJ; van Doorn LJ; Quint WG
    J Clin Virol; 2009 Nov; 46 Suppl 3():S16-20. PubMed ID: 20129069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy.
    Porras C; Wentzensen N; Rodríguez AC; Morales J; Burk RD; Alfaro M; Hutchinson M; Herrero R; Hildesheim A; Sherman ME; Wacholder S; Solomon D; Schiffman M
    Int J Cancer; 2012 Apr; 130(8):1879-87. PubMed ID: 21607948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
    Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
    BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Performance of HPV E6/E7 mRNA and HPV DNA Assays for the Detection and Screening of Oncogenic Human Papillomavirus Infection among Woman with Cervical Lesions in China.
    Wang HY; Lee D; Park S; Kim G; Kim S; Han L; Yubo R; Li Y; Park KH; Lee H
    Asian Pac J Cancer Prev; 2015; 16(17):7633-40. PubMed ID: 26625774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H).
    Cubie HA; Canham M; Moore C; Pedraza J; Graham C; Cuschieri K
    J Clin Pathol; 2014 Jun; 67(6):458-63. PubMed ID: 24436334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
    Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
    J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.